MIMEDX GROUP INC
MDXGNASDAQTrading Snapshot
- Day Range
- $617.85 β $627.41
- 52-Week Range
- $3.03 β $7.97
- Volume
- $3.68B
- Avg Volume
- $3.45B
- Shares Outstanding
- 145.8M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $419M
- Last Q Revenue
- $64M
- P/E Ratio
- 109.1
- P/S Ratio
- 1.9x
- EPS (TTM)
- $0.04
- Dividend Yield
- β
- Dilution (1yr)
- +0.5%
Why Investors Own MDXG
- βHigh-growth profile β revenue up +5.8% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MIMEDX GROUP INC
MDXGAbout MIMEDX GROUP INC
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
MIMEDX GROUP INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MDXG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MIMEDX GROUP INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.